

Ministry of Health

Drugs and Devices Division

Drug Submission Status

Report for January 2021

Complete Streamlined Multiple-Source Submissions for Future Formulary Listing

The Ministry of Health and Long-Term Care has received complete submissions for the following streamlined multiple-source drug products for listing on the Ontario Drug Benefit Formulary. Subject to confirmation of Drug Identification Numbers (DIN) and prices by the manufacturers, as well as review and approval by the Executive Officer, these products may be listed as benefits in a future Formulary update. Final listing status will be communicated when the Formulary update is published on the Ministry website and via a DDD Notice.

Manufacturer	Product	Reference Product	Generic Name	Strength	Dosage Form	DIN
Nora Pharma	NRA-Omeprazole	Losec	OMEPRAZOLE	20 mg	DR tablet	02501880
Nora Pharma	NRA-Ciprofloxacin	Cipro	CIPROFLOXACIN	500 mg	tablet	02492008
Jamp Pharma Corporation	Jamp Dienogest	Visanne	DIENOGEST	2 mg	tablet	02498189
Jamp Pharma Corporation	Jamp Telmisartan	Micardis	TELMISARTAN	40 mg	tablet	02386755
Jamp Pharma Corporation	Jamp Telmisartan	Micardis	TELMISARTAN	80 mg	tablet	02386763

Sandoz Canada Inc.	Sandoz Ciprofloxacin / Dexamethasone	Ciprodex	CIPROFLOXACIN HYDROCHLORIDE & DEXAMETHASONE	0.3 % / w/v & 0.1 % / w/v	otic suspension	02506882
Auro Pharma Inc.	Auro-Buspirone	Buspar	BUSPIRONE HYDROCHLORIDE	10 mg	tablet	02500213
Pharmaris Canada Inc.	PRZ-Solifenacin	Vesicare	SOLIFENACIN SUCCINATE	5 mg	tablet	02493039
Pharmaris Canada Inc.	PRZ-Solifenacin	Vesicare	SOLIFENACIN SUCCINATE	10 mg	tablet	02493047
Accord Healthcare Inc	Methotrexate Injection BP	METHOTREXATE	METHOTREXATE SODIUM	25 mg/mL	Intravenous, Intra-Arterial, Intramuscular solution	02464365